Collagen peptide intake may modulate bone turnover in female endurance athletes

London, United Kingdom — 20 May 2026

A recently published pilot study in Frontiers in Nutrition suggests that four weeks of high-dose collagen peptide (CP) supplementation may positively influence bone formation and inflammation markers in premenopausal female endurance athletes. This cohort faces unique physiological challenges including hormonal fluctuations, high mechanical loading, and potential low energy availability, which can impact bone remodelling and elevate inflammatory stress. The research, conducted by Fitchburg State University and the University of Connecticut, focused on the effects of Vital Proteins CP supplementation within this specific demographic.

The study found that short-term CP supplementation increased serum procollagen type I N-terminal propeptide (P1NP), a key indicator of bone formation, without altering C-terminal telopeptide of type I collagen (CTX-1), which signifies bone breakdown. Furthermore, the intervention stabilised the sRANKL/OPG ratio, a marker of bone metabolism, and reduced circulating interleukin-6 (IL-6), an inflammatory cytokine. These findings suggest a credible pathway for CPs to stimulate osteoblast activity and regulate osteoimmune function in a population subjected to repetitive mechanical stress and skeletal strain, as noted by the researchers.

Twenty-two active female adults aged 18–35, running over 35 miles per week, participated in the randomised, double-blind, placebo-controlled trial. Participants consumed 20g of CP or a placebo daily. Dietary intake and exercise energy expenditure were meticulously tracked, and assessments were timed during the early follicular phase of menstrual cycles to minimise hormonal variability in bone turnover markers. While the study's limitations include a small sample size and short duration, the observed effects underscore the need for larger, longer-term trials to validate whether these biochemical changes translate into meaningful structural bone adaptations and reduced injury risk for female athletes.

What this means for United Kingdom

UK supplement manufacturers and brand owners should note the emerging evidence for targeted collagen applications in active women. This insight supports the development of new product lines specifically addressing female endurance athletes, a demographic often underserved by generalised sports nutrition. Brands can differentiate by incorporating scientifically backed bone health claims for this critical consumer group, moving beyond generic skin/hair/nails benefits typically associated with collagen. Regulatory teams must prepare for potential dossier submissions leveraging these findings, particularly for specific Article 13.1 health claims related to bone formation and inflammatory response. This segment presents a competitive opportunity for early movers, with potential for increased market share in a niche, high-value category.

What to watch next

• Monitor forthcoming regulatory guidance from the FSA and MHRA on bone health claims for collagen post-Brexit, anticipated Q4 2026, which will clarify permissible on-pack messaging.
• Observe the initiation of larger, adequately powered clinical trials on collagen peptide efficacy post-Q2 2027, as these will be crucial for validating mechanisms and supporting bolder commercial claims.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.